相似文献
1
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
Clin Lung Cancer. 2012 Sep;13(5):321-5. doi: 10.1016/j.cllc.2012.05.004. Epub 2012 Jun 6.
2
Biomarkers of Bad Biology: Curse or a Blessing?
Ann Surg Oncol. 2019 Feb;26(2):318-320. doi: 10.1245/s10434-018-07105-w. Epub 2018 Dec 11.
3
The Future of Precision Oncology for the Treatment of Solid Tumors.
Clin Pharmacol Ther. 2020 Sep;108(3):416-418. doi: 10.1002/cpt.1739. Epub 2020 Jan 25.
4
Implications of intratumour heterogeneity for treatment stratification.
J Pathol. 2014 Jan;232(2):264-73. doi: 10.1002/path.4270.
5
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27.
6
Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?
J Natl Compr Canc Netw. 2017 Jul;15(7):859-862. doi: 10.6004/jnccn/2017.0126.
7
Is Precision Medicine an Oxymoron?
JAMA Oncol. 2019 Feb 1;5(2):142-143. doi: 10.1001/jamaoncol.2018.5099.
8
New ESMO scale ranks mutations as cancer medicine targets.
Lancet Oncol. 2018 Oct;19(10):e513. doi: 10.1016/S1470-2045(18)30664-8. Epub 2018 Aug 31.
9
Maurie Markman on the Groundbreaking TAPUR Trial.
Oncology (Williston Park). 2017 Mar 15;31(3):158, 168.
10
Giving Up on Precision Oncology? Not So Fast!
Clin Transl Sci. 2017 May;10(3):128-129. doi: 10.1111/cts.12457. Epub 2017 Feb 21.
引用本文的文献
1
Clinicopathological Features, Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase (ALK) Rearrangement-Based Survival of Patients With Advanced Non-small Cell Lung Cancer in a Tertiary Care Setting.
Cureus. 2024 Dec 23;16(12):e76257. doi: 10.7759/cureus.76257. eCollection 2024 Dec.
2
Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.
J Cancer Res Clin Oncol. 2023 Sep;149(11):9301-9315. doi: 10.1007/s00432-023-04856-2. Epub 2023 May 19.
3
Biospecimen Digital Twins: Moving from a "High Quality" to a "Fit-for-Purpose" Concept in the Era of Omics Sciences.
Cancer Genomics Proteomics. 2023 May-Jun;20(3):211-221. doi: 10.21873/cgp.20376.
4
Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer.
Transl Cancer Res. 2020 May;9(5):3491-3498. doi: 10.21037/tcr.2020.03.72.
5
Current and Prospective Protein Biomarkers of Lung Cancer.
Cancers (Basel). 2017 Nov 13;9(11):155. doi: 10.3390/cancers9110155.
6
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016.
7
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.
Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.
8
Influence of chemotherapy on EGFR mutation status.
Transl Lung Cancer Res. 2013 Dec;2(6):442-4. doi: 10.3978/j.issn.2218-6751.2013.10.12.
9
[Advances on driver oncogenes of non-small cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):42-7. doi: 10.3779/j.issn.1009-3419.2015.01.07.
10
Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell lines.
Cancer Manag Res. 2014 Oct 21;6:431-6. doi: 10.2147/CMAR.S71185. eCollection 2014.
本文引用的文献
1
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
2
Personalized oncology through integrative high-throughput sequencing: a pilot study.
Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.
3
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
4
Evolutionary dynamics of intratumor heterogeneity.
PLoS One. 2011 Mar 30;6(3):e17866. doi: 10.1371/journal.pone.0017866.
5
Implications of personalized medicine--perspective from a cancer center.
Nat Rev Clin Oncol. 2011 Mar;8(3):177-83. doi: 10.1038/nrclinonc.2010.222.
6
The mutation spectrum revealed by paired genome sequences from a lung cancer patient.
Nature. 2010 May 27;465(7297):473-7. doi: 10.1038/nature09004.
7
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
8
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
J Clin Oncol. 2009 Aug 20;27(24):4027-34. doi: 10.1200/JCO.2009.22.3701. Epub 2009 Jul 13.
9
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Clin Lung Cancer. 2009 May;10(3):148-50. doi: 10.3816/CLC.2009.n.020.
10
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
Zotero 插件